Natures Sunshine Products Inc
NATR Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$12.27
KIRA · Stoqly’s AI analyst, in plain words
- Natures Sunshine Products Inc had $480M of revenue in fiscal 2025, up 5.7% on the year before. Over five years, revenue changed +4.5% a year on average.
- Its operating margin was 5.2%, up 0.7 pts: of every 100 in sales, about 5 is left after running the business.
- Natures Sunshine Products Inc made $19.5M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 28.6% a year.
- Free cash flow was $28.8M in fiscal 2025, 6.0% of revenue.
- Natures Sunshine Products Inc returned $16.3M to shareholders in fiscal 2025, 57% of free cash flow. The diluted share count fell 3.3%.
Market cap
$225M
P/E
12.1x
Revenue
$480M
Net income
$19.5M
Free cash flow
$28.8M
Operating margin
5.2%
Natures Sunshine Products Inc in 30 seconds · fiscal 2025
Are sales growing?
+5.7%
Yes. Sales grew 5.7% last year.
Does it make a profit?
4.1%
A little. It keeps 4.1% of every sale as profit.
Does profit turn into cash?
6.0%
Partly. 6.0% of sales ends up as free cash.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
12.1x
One share costs 12.1 times its yearly profit per share.
What Natures Sunshine Products Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- NATURES SUNSHINE PRODUCTS INC
- CIK
- 0000275053
Natures Sunshine Products Inc · NATR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $444M | $422M | $445M | $454M | $480M |
| Revenue growth | 15.3% | −5.0% | 5.5% | 2.0% | 5.7% |
| Gross margin | 74.0% | 71.0% | 72.1% | 71.5% | 72.4% |
| Operating margin | 7.8% | 3.9% | 4.2% | 4.4% | 5.2% |
| Net income | $30.2M | −$0.4M | $15.1M | $7.7M | $19.5M |
| Net margin | 6.8% | −0.1% | 3.4% | 1.7% | 4.1% |
| Diluted EPS | $1.42 | −$0.02 | $0.77 | $0.40 | $1.06 |
| Cash | |||||
| Cash from operations | $34.6M | $0.7M | $41.2M | $25.3M | $35.3M |
| Capital expenditure | $6.7M | $7.6M | $10.5M | $11.0M | $6.5M |
| Free cash flow | $27.9M | −$6.9M | $30.7M | $14.3M | $28.8M |
| FCF margin | 6.3% | −1.6% | 6.9% | 3.2% | 6.0% |
| Dividends paid | $19.9M | $0.0M | — | — | — |
| Share buybacks | $7.4M | $13.6M | $6.4M | $8.9M | $16.3M |
| Share count change | 1.8% | −4.9% | 0.7% | −1.9% | −3.3% |
| Debt and strength | |||||
| Cash and short-term investments | $86.2M | $60.0M | $82.4M | $84.7M | $93.9M |
| Debt incl. finance leases | $2.4M | $1.2M | $0.0M | — | — |
| Shareholders' equity | $161M | $147M | $160M | $161M | $162M |
| Net debt / EBITDA | −1.8x | −2.2x | −2.7x | — | — |
| Current ratio | 2.1x | 2.3x | 2.2x | 2.4x | 2.3x |
| Interest coverage | 138.7x | 65.3x | 271.7x | 137.6x | 252.5x |
| Returns and quality | |||||
| Return on capital | 42.4% | 12.0% | 19.7% | — | — |
| Return on equity | 19.0% | −0.3% | 9.8% | 4.8% | 12.1% |
| Return on tangible equity | 17.9% | −0.3% | 9.4% | 4.8% | 12.1% |
| Piotroski F-score | 7 | 6 | 6 | 6 | 6 |
| Altman Z'' | 5.3 | 5.2 | 5.3 | 6.0 | 5.8 |
Insiders bought, 12 months
$2.6M
2 insiders
Insiders sold, 12 months
$2.1M
5 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Natures Sunshine Products Inc · NATR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $12.27 a share, the company is worth $225M: 12.1 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0000275053). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.